ICON plc (ICLR)

ICON plc reported third-quarter 2026 revenue of $2,024.8 million on October 27, 2026, a decrease of 2.9% from the third quarter of 2025 1. Adjusted EBITDA, profit before interest, tax, depreciation and one-off items, was $336.9 million, a margin of 16.6% 1. Net income under US accounting rules was $122.1 million, or $1.58 per diluted share 1.

Net business wins, meaning orders signed less cancellations, were $3,150 million, a book-to-bill ratio of 1.56 1. Backlog, signed work not yet done, was $24.5 billion at September 30, 2026 1. The company repurchased $400.0 million of its shares in the quarter 1.

The Audit Committee found that revenue was overstated in 2023 and 2024, and the annual report restated those years 53.

A securities class action in New York is pending 2. ICON and other defendants asked the court to dismiss it on September 1, 2026, and briefing is due to finish by November 24, 2026 2.

ICON was founded in Dublin, Ireland in 1990 and grew into a contract research organization, a company that runs drug trials and related services for drug and device makers 3. It expanded through organic growth and a number of acquisitions that added skills and scale 3.

The biggest step was the purchase of PRA Health Sciences, completed by merger on July 1, 2021 3. ICON financed it in part with a senior secured term loan facility of $5,515.0 million 3. By the end of 2025 it had repaid $4,598.3 million of that loan, leaving $916.7 million outstanding 3.

It took full control of the oncology research site network Oncacare on April 20, 2023, and acquired BioTel Research, a medical imaging and cardiac safety business, on October 2, 2023 3. It acquired the technology firm HumanFirst on January 9, 2024 and the clinical research firm KCR on August 19, 2024 3.

Revenue rose 1.7% to $8,189.0 million in 2024, which the company put down to acquisitions and organic growth 3. It then rose 0.8% to $8,251.3 million in 2025 3.

US revenue fell 15.4% to $2,524.9 million in 2025, while revenue in Ireland rose 17.7% to $3,183.6 million 3. The company says these movements reflect its global contracting model 3.

The Audit Committee began an investigation into accounting practices in late October 2025 4. On February 12, 2026 ICON said 2023 and 2024 revenue may have been overstated by less than 2% in each year 4. It withdrew its 2025 full year guidance the same day 4.

TipRanks reported that ICON then filed a notice of late filing for its annual report while it reworked several years of statements 6. On April 29, 2026 the committee said its investigation was complete 5. The annual report put the overstatement at $92.7 million for 2024 and $65.3 million for 2023 3.

In 2025 ICON recorded a goodwill impairment charge of $364.2 million, the entire goodwill of its Data Solutions unit, after revising its expectations for that unit 3. Income from operations fell 57.1% to $442.8 million 3. Barry Balfe succeeded Steve Cutler as chief executive on October 1, 2025 3.

What ICON sells

ICON offers clinical development, functional outsourcing and laboratory services 3. Clinical development covers every phase of drug testing, from Phase I to Phase IV, plus data solutions and help finding sites and patients 3. Laboratory services include testing for biomarkers and vaccines and central lab work 3.

The company reports one segment, outsourced development services supplied worldwide to drug, biotechnology and device makers 3. Its five largest customers brought in $2,046.2 million, or 24.8% of revenue, in 2025 3.

Where the work is booked

In 2025 the company drew 30.6% of revenue from the United States, 57.9% from Europe and 11.5% from the rest of the world 3. Revenue booked in Ireland was $3,183.6 million 3. Irish entities act as the group entrepreneur under its transfer pricing model 3.

Accellacare and patient access

Accellacare is ICON's global clinical research network, offering stand-alone and integrated solutions at trial sites or in patients' homes 3. Its site network has 21 owned or embedded sites across the US, UK and Spain 3. Its in-home service takes study visits to patients in more than 55 countries 3.

People

Barry Balfe is chief executive and Nigel Clerkin is chief financial officer 1. ICON employed approximately 40,250 people in 98 locations in 55 countries at September 30, 2026 1. Ciaran Murray chairs the board 4.

Rivals

The annual report calls the contract research industry highly competitive 3. It says ICON competes with other large global CROs for strategic relationships with large pharmaceutical companies 3.

Current problems

Management concluded that internal control over financial reporting was not effective at December 31, 2025 because of material weaknesses, which are control gaps that could let a material error through 3. The remediation plan is not complete 3.

A securities class action, In re ICON plc Securities Litigation, is pending in the federal court for the Eastern District of New York 2. It alleges misleading statements about financial performance and names the company and current and former executives 2. The company has not formed a view on the outcome 2.

The umbrella, in words

The annual report lists the group's significant subsidiaries by country 3. US entries include ICON Clinical Research LLC and PRA Health Sciences, Inc., both shown at 100% ownership 3.

ICON Investments Six Designated Activity Company, a wholly owned subsidiary, issued $2.15 billion of senior unsecured notes on August 13, 2026 2. ICON plc guarantees them 2.

On May 8, 2026 ICON completed the disposition of Symphony Health Solutions to HealthVerity for shares of HealthVerity stock 3. ICON also purchased more HealthVerity shares for $37.5 million and reports a minority equity interest, carried at nil 3.

Five shareholders are reported above 5% of the ordinary shares as of May 22, 2026: Artisan Partners at 10.91%, Wellington Management at 7.72%, Harris Associates at 5.68%, FMR at 5.45% and Invesco at 5.06% 3. None has voting rights that differ from any other listed 3.

With its release of October 27, 2026 the company updated its 2026 guidance to revenue of $8,100 - $8,200 million and adjusted diluted earnings per share of $10.35 - $10.65 1.

Barry Balfe said the updated guidance reflects operational progress and higher pass-through activity 1. He said the results reinforce confidence in delivering "revenue growth, significant earnings progression, and shareholder value creation in 2027 and beyond" 1.

The board approved a larger share buyback authorization, bringing the total authorized to $750.0 million, to be deployed opportunistically 1.

The annual report says remediation of the control weaknesses is ongoing, with no assurance on when the plan will be fully implemented 3. It also says ICON has not paid cash dividends and does not currently intend to 3.

The motion to dismiss the securities class action is scheduled to be fully briefed by November 24, 2026 2. The August 2026 notes fall due in 2029, 2031 and 2036, with interest payable from February 13, 2027 2.